https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-superior-to-skyrizir-risankizumab-in-be-bold-first-head-to-head-study-in-active-psoriatic-arthritis-psa-to-demonstrate-superiority-in-acr50
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...
Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as...
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.01894/full
Frontiers | Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally s...
https://medlineplus.gov/druginfo/meds/a623049.html
Bimekizumab-bkzx injection: MedlinePlus Drug Information
Bimekizumab-bkzx injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
bimekizumabinjectionmedlineplusdruginformation
https://pubmed.ncbi.nlm.nih.gov/39313302/
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of...
ClinicalTrials.gov: NCT03895203; NCT03896581.
https://www.cigna.com/knowledge-center/hw/medications/bimekizumab-bkzx-injection-a623049
Bimekizumab-bkzx injection | Cigna
Bimekizumab-bkzx injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in...
bimekizumabinjectioncigna